Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | ABL2 | P42684 | 1/20 | 0.58 |
| ▸ | BLK | P51451 | 1/20 | 0.58 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.58 |
| ▸ | WDR5 | P61964 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028892 | 0.92 | AURKA (0.62) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL11028586 | 0.89 | AURKA (0.57) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL11027793 | 0.88 | AURKA (0.57) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL11029261 | 0.87 | AURKA (0.57) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL1160827 | 0.87 | AURKA (0.57) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL11028991 | 0.87 | AURKA (0.54) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL11025553 | 0.87 | AURKA (0.55) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL11028898 | 0.87 | AURKA (0.59) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL1161178 | 0.87 | AURKA (0.53) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL11031701 | 0.85 | AURKA (0.62) | AURKAAURKBCHEK2CSF1RRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | claimed |
| EP-2461869-B1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | claimed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | claimed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2461869-B1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| WO-2011017142-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | CCNC, CCNI, CCNA1 | AURKA 566/4885AURKB 446/4885CHEK2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.